Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals (TLX) has expanded its partnership with GE Healthcare via a deal to supply its investigational positron emission tomography (PET) imaging radiotracers
- The company penned the collaborative development and reseller agreement to supply TLX250-CDx and FLac for use in third party clinical research and development activities
- Under the agreement, GE Healthcare will be responsible for the direct marketing and sales of Telix’s imaging agents to pharmaceutical companies
- The agreement has an initial term of five years, subject to review
- Telix Pharmaceuticals shares are up 0.55 per cent, trading at $5.44 at 1:41 pm AEDT
Telix Pharmaceuticals (TLX) has expanded its partnership with GE Healthcare, via a deal to supply its investigational positron emission tomography (PET) imaging radiotracers.
The company penned the collaborative development and reseller agreement to supply TLX250-CDx and FLac for use in third party clinical research and development activities.
The novel tracers offer the potential to provide key information regarding the metabolic environment of tumours, which could help to inform and improve therapy selection.
Under the agreement, GE Healthcare will be responsible for the direct marketing and sales of Telix’s imaging agents to pharmaceutical companies.
Telix will remain responsible for manufacturing and ongoing development of each product.
“This partnership will see our investigational imaging agents used more widely in third-party clinical trials,” Telix SVP Global Business Development and Alliance Management Jonathan Barlow said.
“Excitingly, it will also help to expedite the development of FLac, while expanding the utility of our TLX250-CDx imaging candidate.”
The agreement has an initial term of five years, subject to review.
Telix Pharmaceuticals shares were up 0.55 per cent, trading at $5.44 at 1:41 pm AEDT.
